$0.46
-0.45%Xtant Medical Holdings, Inc. develops, manufactures, and markets regenerative medicine products and medical devices for orthopedic and neurological surgeons in the United States and internationally. Its biomaterial products include OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSponge SC that fills bony defects in the subchondral region of joints; OsteoSelect DBM Putty for osteoinductive bone growth; OsteoSelect PLUS DBM Putty for use as a bone void filler and bone graft substitute in the pelvis, extremities, and posterolateral spine; OsteoFactor, which contains various proteins and peptides that support bone formation and remodeling; OsteoWrap; and OsteoVive Plus, a growth factor enriched cellular bone matrix. The company also provides 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone. In addition, it processes and distributes sports allografts for anterior and posterior cruciate ligament repairs, anterior cruciate ligament reconstruction, and meniscal repair; milled spinal allografts for cortical bone milled to desired shapes and dimensions; and traditional allografts for orthopedics, neurology, podiatry, oral/maxillofacial, genitourinary, and plastic/reconstructive applications. Further, the company offers Certex spinal fixation, Spider cervical plating, Axle interspinous fusion, Silex Sacroiliac joint fusion, Xpress minimally invasive pedicle screw, and Fortex Pedicle screw systems. Additionally, it provides Calix for cervical and thoracolumbar applications, Axle-X interspinous fusion system, Irix-C cervical integrated fusion system, and Irix-A Lumbar integrated fusion system. The company was formerly known as Bacterin International Holdings, Inc. and changed its name to Xtant Medical Holdings, Inc. in July 2015. Xtant Medical Holdings, Inc. is headquartered in Belgrade, Montana.
Exceptional pricing power and cost management. The company retains over half of revenue after direct costs.
Acceptable margins but limited operational leverage. Operating expense control is important.
Minimal profitability after all expenses. Limited financial flexibility for reinvestment or shareholder returns.
Higher tax burden may reflect limited tax optimization or operations in high-tax jurisdictions.
Margin squeeze alert: Healthy gross margins but weak operating margins suggest excessive operating expenses. Cost optimization could unlock significant value.
XTNT โข AMEX
| Xtant Medical Holdings, Inc. Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
REVENUE | ||||||||||||||||||
133.9M | 117.3M | 91.3M | 58M | 55.3M | 53.3M | 64.7M | 72.2M | 82.6M | 90M | 59.3M | 35.3M | 33.1M | 33M | 30.1M | 15.4M | 7.4M | 459.2K | |
GROSS PROFIT | ||||||||||||||||||
(49.7M) | (49.1M) | (35.8M) | (25.8M) | (22.8M) | (18.9M) | (22.2M) | (28.7M) | (32.5M) | (27.7M) | (20.3M) | (13M) | (14.2M) | (10.3M) | (9.1M) | (3.4M) | (2.3M) | (386.5K) | |
84.3M | 68.2M | 55.5M | 32.1M | 32.5M | 34.4M | 42.5M | 43.5M | 50.1M | 62.3M | 39.1M | 22.3M | 18.9M | 22.6M | 21M | 12.1M | 5.1M | 72.7K | |
OPERATING INCOME | ||||||||||||||||||
(77M) | (80.3M) | (65.6M) | (38.9M) | (36.3M) | (35.1M) | (44.8M) | (50.9M) | (63.8M) | (68.4M) | (48.3M) | (27.6M) | (27.2M) | (27.6M) | (27.5M) | (20.7M) | (8.7M) | (88.6K) | |
(74.9M) | (77.9M) | (64.3M) | (38M) | (35.5M) | (34.5M) | (43.8M) | (45.1M) | (55.8M) | (60.1M) | (42M) | (25.9M) | (26.8M) | (27.2M) | (26.7M) | (20M) | (4.2M) | (88.6K) | |
(2.1M) | (2.4M) | (1.3M) | (915K) | (870K) | (657K) | (932K) | (1.7M) | (2.4M) | (3.4M) | (2.5M) | (1.4M) | (572.4K) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
7.3M | -12.1M | -10.2M | -6.8M | -3.9M | -751K | -2.4M | -60.1M | -37.8M | -7.5M | -12.1M | -6.3M | -9M | -4.9M | -6.5M | -8.6M | -3.6M | -15.8K | |
PRE-TAX INCOME | ||||||||||||||||||
(3.7M) | (4.2M) | (2.9M) | (1.7M) | (995K) | (6M) | (5.8M) | (10.1M) | (14.7M) | (12.3M) | (7.7M) | (5.7M) | (4.7M) | (1.9M) | (1.2M) | (1.6M) | (513.9K) | (0.0) | |
-3.6M | -4.2M | -2.8M | -1.7M | -995K | -6M | -5.8M | -10.1M | -14.7M | -12.3M | -7.7M | -5.7M | -4.7M | -1.9M | -1.2M | -1.6M | -500.9K | 0.0 | |
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (58K) | (3K) | -74.7K | -351.9K | (388.2K) | (0.0) | (0.0) | -1.6M | (755.4K) | (633.8K) | (72.3K) | (0.0) | |
-283K | -4.2M | 9.1M | -1.7M | -995K | -6M | -5.9M | -10M | -14.6M | -11.9M | -7.6M | -4.2M | -3.7M | -2.8M | 3.4M | -10.9M | 3.6M | 0.0 | |
7M | -16.3M | -1M | -8.4M | -4.8M | -6.7M | -8.1M | -70.1M | -52.4M | -19.4M | -19.7M | -10.5M | -12.7M | -7.7M | -3M | -19.5M | -4.1M | -15.8K | |
NET INCOME | ||||||||||||||||||
(2M) | (187K) | -1.7M | (69K) | (0.0) | (296K) | (98K) | (124K) | (0.0) | (50.4K) | -17.5M | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (1.8K) | (0.0) | |
5M | -16.4M | 660K | -8.5M | -4.8M | -7M | -8.2M | -70.1M | -52.4M | -19.5M | -2.2M | -10.5M | -12.7M | -7.7M | -3M | -19.5M | -4.1M | -15.8K |
XTNT - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
10-Q 10-Q 2026 Q1 Q1 | May 13, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 13, 2026 | May 13, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 13, 2026 | April 10, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 31, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 31, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 02, 2026 | March 02, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 16, 2026 | January 15, 2026 | 2026 | |
8-K 8-K 2025 N/A | December 03, 2025 | December 01, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 10, 2025 | November 07, 2025 | 2025 | |
10-Q 10-Q 2025 Q3 Q3 | November 10, 2025 | September 30, 2025 | 2025 |
Continue your XTNT research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.